Quercetin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Quercetin is a plant compound in many foods, used with the drug dasatinib to clear worn-out cells. The pair does clear those cells in people. Proper studies have not shown that this makes anyone healthier.
Evidence grade for Quercetin: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 3 completed trials, 60 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 60
- Human studies
- 3
- Found nothing
- 1
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
3 completed trials, 60 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Muscle and strength
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Quercetin is a plant compound found in many foods. It is sold as a supplement. People pair it with the cancer drug dasatinib to clear out worn-out cells that build up with age. The pair is called D+Q.
What people take it for
- Clearing worn-out cells to slow ageing.
- Less inflammation.
- Pairing with dasatinib in a D+Q plan.
What studies in people showed
The most careful study had 60 women past menopause. D+Q did no better than no treatment on a blood marker of bone loss after 20 weeks. In lung scarring, a first study of 14 people found they walked better. But there was no one to compare them with. When the same team added a dummy pill group, 12 people took part, and the gains did not show up. Side effects were far more common on the drugs, 65 reports against 22. In kidney disease from diabetes, three days of D+Q did cut the number of worn-out cells. In mice, the pair helped old mice work better.
What people report
Reports, not study results
The good
- In the studies on this page, D+Q did clear worn-out cells in people with kidney disease from diabetes.
The bad
- In the lung scarring study with a dummy group, people on the drugs had 65 side effect reports against 22 on the dummy.
Where these come from: Both lines are from the studies on this page. We have not collected forum or user reports for this one yet.
My bottom line
Clearing the cells is proven. Feeling or working better from it is not. The careful studies missed. I would not build a plan on this.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Quercetin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Getting stronger14 people · 2 studies
35 of the 36 indexed goals have no study of any kind behind Quercetin
No study in people, animals or cells on this page reports a result for these. That does not prove Quercetin does nothing for them. It does mean anything you have heard about Quercetin and one of these did not come from a study cited here.
Show full evidence
What is Quercetin?
Quercetin is a plant compound in many foods, used with the drug dasatinib to clear worn-out cells. The pair does clear those cells in people. Proper studies have not shown that this makes anyone healthier.
Quercetin is a plant compound found in lots of foods. It also helps clear out worn-out cells that build up with age. It is best known as the partner to the cancer drug dasatinib, a pair called D+Q. In 60 women past menopause, D+Q did no better than no treatment on a blood marker of bone loss after 20 weeks. In lung scarring, a first study of 14 people found they walked better, but there was no one to compare them with. When the same team added a dummy-pill group, 12 people took part and the gains did not hold up. In people with diabetic kidney disease, three days of D+Q did cut the number of worn-out cells. On its own, quercetin's effect on these cells is modest. No drug of this kind has yet made people healthier in a proper study.
How does Quercetin work?
It helps push worn-out cells to die, mostly when paired with dasatinib. It also turns down swelling signals.
The evidence, in charts
Fig. 1a · how many people
74people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| Nature Medicine 2024 | 60 | 81% |
| EBioMedicine 2019 | 14 | 19% |
One study holds 81% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
4 of 5 sources here are studies in people. The rest is not.
- Study in people · done in people480%
- Animal study · done in animals120%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2015 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Supplement
- Molecule weight
- 302.2 Da
- Half-life
- About 19.5 hoursMedium, 6 to 24 hours
- Chain length
- None on file
No amino acid sequence is on file for Quercetin, which is expected: a supplement is not built from amino acids.
The studies we cite
- Study in people2024Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
It was tested properly and it missed. 60 women past menopause got the dasatinib and quercetin pair or no treatment. The main measure, a blood marker of how fast bone is being broken down, came out the same in both groups after 20 weeks. This is the most careful study of these drugs reported so far, and on its own terms it is negative.
60 postmenopausal women randomised to dasatinib plus quercetin or control: the primary endpoint, change in the bone resorption marker CTx at 20 weeks, did not differ between groups.
- Study in people2023Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: a phase I, single-blind, randomized, placebo-controlled pilot trial
When the same team repeated their pilot with a dummy group added, the benefit vanished. Twelve people took part. Frailty, lung function and physical function came out much the same whichever they were given. Side effects were far more common on the drug, 65 reports against 22. Twelve people is tiny. The difference between the two studies is still the thing to notice.
The same team's open-label pilot repeated with a placebo arm, n=12: frailty, pulmonary and physical function did not appear to differ meaningfully between groups, and the drug arm reported 65 non-serious adverse events against 22 on placebo.
- Study in people2019Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease
The drugs do what they are claimed to do inside the body. People with diabetic kidney disease took the pair for three days. Within 11 days, the number of worn-out cells in their fat and skin had fallen, and so had the inflammatory signals those cells give off. That is the mechanism confirmed in a living person. Whether clearing those cells makes anyone healthier is a different question, and it is unanswered.
Three days of D+Q reduced adipose and skin senescent cells and circulating SASP factors within 11 days.
- Study in people2019Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study
Everyone here knew they were getting the drugs, and they walked better afterwards. 14 patients with lung scarring took part. Distance covered in six minutes, walking speed and time to rise from a chair all improved. There was nobody to compare them against. People who join a trial and receive close attention often improve anyway, which is precisely why the same team later added a dummy group.
14 patients: D+Q was feasible and improved 6-minute walk, gait speed and chair-stand time; no control group.
- Animal study2015The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
In mice: this study found dasatinib plus quercetin, the first drug pair shown to clear worn-out cells. It helped old mice, and mice bred to age fast, function better.
Identified dasatinib plus quercetin as the first senolytic combination, improving function in aged and progeroid mice.
Common questions
Has Quercetin been tested in people?
Yes. 60 people given it across 3 completed trials cited here, 1 of which found nothing. Quercetin is a plant compound in many foods, used with the drug dasatinib to clear worn-out cells. The pair does clear those cells in people. Proper studies have not shown that this makes anyone healthier.
What is the Quercetin dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 3 completed trials, 60 people given it
Is Quercetin FDA-approved?
Sold as a supplement; used in research on clearing out worn-out (senescent) cells
Why is quercetin paired with dasatinib?
Dasatinib and quercetin clear different kinds of worn-out cells. In research, the pair, called D+Q, clears more than either one alone.
Latest reading on Quercetin
Blog posts about Quercetin, newest first.
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 27, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 27, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
- Longevity / Sep 27, 2026 / 8 minKlotho Explained: Protein, Peptide, Gene Therapy or Supplement?